Merck’s Positive Winrevair Data Expected To Drive PAH Market Growth

 
• By Alaric DeArment
  
Pulmonary hypertension is a cardiovascular condition characterized by high blood pressure in the pulmonary arteries 3D rendering
Merck announced data from the Phase III HYPERION trial of Winrevair in patients with PAH earlier after diagnosis. • Source: Shutterstock

More from Clinical Trials

More from R&D